非布司他与别嘌醇治疗慢性肾脏病伴高尿酸血症的临床效果比较

Abstract
Figure/Table
References (19)
Related Citation (15)

Download: PDF (0 KB) HTML (39 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To compare the clinical effect of Febuxostat and Allopurinol in the treatment of chronic kidney disease (CKD) combined with hyperuricemia (HUA). Methods A total of 60 patients with CKD (stage 2-4) combined with HUA who were treated in our hospital from January 2017 to May 2019 were selected as research subjects. They were randomly divided into observation group (n=30) and control group (n=30) based on odd/even number. On the basis of routine treatment, patients in the observation group were treated with Febuxostat to reduce uric acid, and in the control group, patients were treated with Allopurinol to reduce uric acid. The treatment lasted for six months. The levels of blood uric acid, serum creatinine, blood urea nitrogen and the glomerular filtration rate (eGFR) before and after treatment were compared in the two groups. The total effective rate of treatment, incidence rates of eGFR decrease＞10%and adverse reaction were compared between the two groups. Results The total effective rate of treatment in the observation group was higher than that in the control group, and the difference was statistically significant (P＜0.05). The incidence rate of eGFR decrease＞10% of patients in the observation group was lower than that in the control group, and the difference was statistically significant (P＜0.05).The levels of blood uric acid,serum creatinine and blood urea nitrogen of the two groups after treatment were lower than those of their respective group before treatment, and the differences were statistically significant(P＜0.05).After treatment,the levels of blood uric acid,serum creatinine and blood urea nitrogen in the observation group were lower than those in the control group, with statistically significant differences(P＜0.05). There was no statistically significant difference in eGFR between the two groups after treatment (P＞0.05).There was no statistically significant difference in the total incidence rate of adverse reactions between the two groups(P＞0.05). Conclusion Both Febuxostat and Allopurinol can effectively treat patients with mild or moderate renal insufficiency combined with HUA. They can markedly reduce blood uric acid levels and improve renal function. The clinical effect of Febuxostat is more obvious than that of Allopurinol. No serious adverse reactions occur in either group.

Key words： Chronic kidney disease Hyperuricemia Febuxostat Allopurinol

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Qing
	PENG Wei-ping
	YANG Wen-zao

Cite this article:

ZHANG Qing,PENG Wei-ping,YANG Wen-zao. Clinical effect comparison of Febuxostat and Allopurinol in the treatment of chronic kidney diseases combined with hyperuricemia[J]. 中国当代医药, 2020, 27(16): 98-101.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I16/98

[1]	Miao Y，Ottenbros SA，Laverman GD，et al.Effect of a reduction in uric acid on renal outcomes during losartan treatment:a posthoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the AngiotensinⅡAntagonist Losartan Trial[J].Hypertension，2011，58（1）：2-7.
[2]	FDA.ULORIC（febuxostat）tablet for oral use[EB/OL].http：//www.accessdata.fda.gov/drugsatfda-docs/label/2009/021856l bl.pdf.
[3]	上海慢性肾脏病早发现及规范化诊治与示范项目专家组.慢性肾脏病筛查诊断及防治指南[J].中国实用内科杂志，2017，37（1）：28-34.
[4]	中国医师协会肾脏内科医师分会.中国肾脏疾病高尿酸血症诊治的实践指南（2017 版）[J].中华医学杂志，2017，97（25）：1927-1936.
[5]	中国慢性肾脏病患者合并高尿酸血症诊治共识专家组.中国慢性肾脏病患者合并高尿酸血症诊治专家共识[J].中华肾脏病杂志，2017，33（6）：463-469.
[6]	秦林芳，张瑞敏，杨素霞，等.非布司他对慢性肾脏病合并高尿酸血症患者的临床效果及对炎症水平的影响[J].中医临床研究，2019，11（13）：126-129.
[7]	王海燕．肾脏病学[M].3 版.北京：人民卫生出版社，2008：48.
[8]	詹宏义，卿松，罗利平，等.不同剂量非布司他治疗慢性肾脏病伴高尿酸血症的临床研究[J].中华肾病研究电子杂志，2018，7（2）：71-73.
[9]	宋柳全，谭焕原，谢宝超，等.非布司他在慢性肾脏病合并高尿酸血症治疗中的应用价值分析[J].山东医药，2019，59（14）：54-56.
[10]	冯哲，陈香美.重视并规范肾脏疾病高尿酸血症的诊治[J].中华医学杂志，2017，97（25）：1921-1922.
[11]	卢金，雷立清，何仁亮.别嘌醇致药疹的基因检测2 例并文献复习[J].新医学，2017，48（6）：421-424.
[12]	李晓英，黄辉，杨丹丹，等.非布司他与别嘌醇治疗痛风伴肾功能不全患者的效果比较[J].中国当代医药，2018，25（13）：151-153.
[13]	黄新忠，薛海燕，袁莉.非布司他对慢性肾脏病3-5 期合并高尿酸血症患者的肾脏保护作用及相关机制[J].中国现代医学杂志，2017，27（26）：97-101.
[14]	Hosoya T，Ohno I.A repeated oral administration study of febuxostat （TMX-67），a non-purine-selective inhibitor of xanthine oxidase，in patientswith impaired renal function in Japan：pharmacokinetic and pharmacodynamic study[J].J Clin Rheumatol，2011，17（4 Suppl 2）：S27-S34.
[15]	王惠芳，张伟，李宁，等.非布司他治疗慢性肾脏病3～5期伴高尿酸血症患者的疗效分析及对肾功能的影响[J].中华高血压杂志，2018，26（9）：900.
[16]	杨杰，沈丰平，周全荣.非布司他治疗慢性肾脏病3～4 期合并高尿酸血症的临床观察[J].医学信息，2017，30（15）：62-64.
[17]	赖爱云，徐健，陶丽.非布司他片联合依托考昔治疗痛风性关节炎的效果及对血清炎症因子的影响[J].中国医药导报，2018，15（9）：101-104.
[18]	赵益.非布司他治疗慢性肾脏病伴高尿酸血症的安全性分析[J].当代医学，2019，25（1）：64-66.
[19]	刘华山.非布司他治疗伴有高尿酸血症痛风患者的疗效及对相关炎性因子的影响[J].中国医学创新，2019，16（10）：66-70.